Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Bevacizumab, Tremelimumab +/- TACE in Advanced HCC or BTC
NCT03937830Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, bevacizumab, tremelimumab in hepatocellular carcinoma (HCC), biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Started Mar 2021; status: active, not recruiting.
02
Drugs
durvalumabbevacizumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT03937830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937830.